Latest news for Kobenhavns Lufthavne (OTC:CPNHF) Stock

Kobenhavns Lufthavne owns and operates Airports in Denmark. The company manages the infrastructure, buildings, and other services in the Kastrup and Roskilde airports. Copenhagen Airports divides its activities into two areas; Aeronautical and Non-aeronautical. Its majority of revenues are derived from the Aeronautical segment which comprises the operations and functions that the airports at Kastrup and Roskilde make available so that airlines can operate their flights, including facilities required for passengers to pass through these airports. The Non-aeronautical segment comprises the other facilities and services provided at the airports for passengers and others, including car-parking facilities, shops, restaurants, rest areas, lounges, and hotels.

COPENHAGEN AIRPORT by Copenhagen Airport A/S

Kobenhavns Lufthavne

News

MBOT

Microbot Medical Announces First Clinical Procedure Using LIBERTY Endovascular Robotic Surgical System At Brigham And Women's Hospital; Trial To Support Future FDA Submission For Commercialization

Strong Business Momentum and Share Trading Performance Trigger Conversion of Outstanding Convertible Notes, Completing the Elimination of $260 Million of Debt from Balance Sheet
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.corescientific.com%2F&amp;esheet=54091188&amp;newsitemid=20240708370287&amp;lan=en-US&amp;anchor=Core+Scientific%2C+Inc.&amp;index=1&amp;md5=ac2499d96688eccbe8845a6cb2cf7021">Core Scientific, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) ("Core Scientific" or the "Company"), one of the largest owners and operators of high-powered digital infrastructure for bitcoin mining and hosting services in North America, today announced the mandatory conversion of its outstanding Secured Convertible Notes due 2029 (the "Notes") pursuant to the Indenture, dated as of January 23, 2024 (the "Indenture"), by and among the Company, as issuer, Wilmington Trust, National Association ("Wilmington Trust"), as trustee and collateral agent, and the other parties thereto.

Financing

Core Scientific, Inc. - Class A Common Stock

CORZ

Core Scientific Announces Strong Business Momentum And Share Trading Performance Trigger Conversion Of Outstanding Convertible Notes, Completing The Elimination Of $260M Of Debt From Balance Sheet

Kandi Technologies Group, Inc. (NASDAQ GS: KNDI) ("Kandi" or the "Company"), a leader in all-electric personal transportation and utility vehicles, announced a strategic cooperation framework agreement ("Agreement") among Kandi, SC Autosports ("Kandi America"), the wholly-owned subsidiary of Kandi in the United States, and Hartford Industrial Co., Ltd. ("Hartford Industrial"), a respected Taiwanese company specializing in the research, development, and manufacturing of recreational motorcycles. The collaboration aims to leverage the strengths of all the parties to enhance product quality and increase market competitiveness.
Key elements of the Agreement include:
<ol>
<li>Kandi commits to authorize Hartford Industrial to manufacture its self-developed off-road vehicles for export to the United States, including Untility-task vehicles (UTV), golf carts, and low-speed vehicles. &nbsp;</li>
<li>Hartford Industrial commits to fully utilizing Kandi-manufactured components for the vehicles authorized for production. Additionally, Hartford Industrial guarantees that these vehicles will be exclusively sold through Kandi America. &nbsp;</li>
<li>The aforementioned off-road vehicles began trial production at Hartford Industrial in July 2024. Mass production preparations are targeted to be completed by the end of 2024. In addition, Hartford Industrial plans to ramp up full-scale production for all Kandi-authorized vehicle models by early 2025.</li>
</ol>

Global

KNDI

Kandi Signs Strategic Cooperation Framework Agreement Among Kandi, SC Autosports And Hartford Industrial Co To Produce Off-Road Vehicles In Taiwan

WIIM

SEDG

SolarEdge Technologies shares are trading higher after B of A Securities upgraded the stock from Underperform to Neutral.

GordonMD Global Investments Announces Radionetics Oncology's Strategic Agreement With Eli Lilly; Radionetics Receives $140M Upfront, Lilly Secures Exclusive Right To Acquire For $1B

SCNI

Scinai Immunotherapeutics Receives Receipt Of Updated LoI From European Investment Bank Providing Specific Terms For Conversion Of It Loan To Equity

OPTT

Ocean Power Technologies shares are trading higher after the company signed a reseller agreement with Survey Equipment Services focused on the provision of OPT's unmanned surface vehicles in the US.

25-megawatt battery energy storage system to enhance utility's system reliability as the largest standalone battery installation to date in the Pacific Northwest
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fameresco.com%2F&amp;esheet=54090605&amp;newsitemid=20240708076006&amp;lan=en-US&amp;anchor=Ameresco%2C+Inc.&amp;index=1&amp;md5=97d1373dbf06b71b9dbfdb6092d62e19">Ameresco, Inc.</a>, (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>), a leading cleantech integrator specializing in energy efficiency and renewable energy, today announced it has signed a contract with Snohomish County Public Utility District (PUD) to construct a battery energy storage system (BESS) with a 20-year guaranteed capacity of 25 megawatts (MW) and 100 megawatt-hours (MWh).

Contracts

AMRC

Ameresco Announces A New Contract For A Battery Energy Storage System Asset With Snohomish County Public Utility District; No Financial Terms Disclosed

AMC Records Busiest Domestic Wednesday Through Sunday Period Of 2024 With 4.2 Million Moviegoers From July 3-7; DESPICABLE ME 4 Merchandise Drives Highest Revenue Program Of The Year; Achieves Highest Wednesday Food And Beverage Revenue Since 2020

Ocean Power Technologies Signs A Reseller Agreement With Survey Equipment Services Focused On The Provision Of OPT's Unmanned Surface Vehicles In The US

Spectral AI, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has signed a Memorandum of Understanding ("MOU") with global medical device company and burn wound therapy leader PolyNovo Limited ("PolyNovo") under which the companies will collaborate to assist Spectral AI in a potential limited deployment of its DeepView System for burn indication in Australia. &nbsp;
Under the MOU, PolyNovo will support Spectral AI's application to the Australian Special Access Scheme (SAS) with an ultimate goal of allowing Spectral AI to deploy up to two DeepView Systems at the Royal Adelaide Hospital and The Alfred Hospital in Melbourne to lay the groundwork for the Company's eventual commercial roll-out based on clinician evaluations and experiences.&nbsp;&nbsp;

MDAI

Spectral AI Signs MOU With PolyNovo To Introduce DeepView System For Burn Indication To Australian Market

Website Will Allow Shareholders to Learn More About Bitfarms' Broken Corporate Governance, the Need for Urgent Board Change and Riot's Three Highly Qualified, Independent Director Nominees

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

BITF

RIOT

Riot Launches www.ABetterBitfarms.com In Connection With Requisition Of Special Meeting Of BitFarms Shareholders

Earnings

JFBR

Jeffs' Brands Announces Preliminary Unaudited Financial Results For Fort Products; H1 2024 Amazon Revenues Reach $4.47M, Up 62% YoY; Estimated Profit $676K, Up 114% YoY

NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the completion of patient enrollment in the pivotal Phase 3 TANDEM clinical trial evaluating the fixed-dose combination ("FDC") of obicetrapib plus ezetimibe in adult patients with Heterozygous Familial Hypercholesterolemia ("HeFH") and/or Atherosclerotic Cardiovascular Disease ("ASCVD") or multiple risk factors for ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-modifying therapies.

Biotech

General

NAMS

NewAmsterdam Pharma Completes Enrollment In Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination Of Obicetrapib Plus Ezetimibe In Patients With HeFH And/Or ASCVD Or ASCVD Risk Factors

CPI Aerostructures, Inc. ("CPI Aero&#xAE;" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVU#NYSE">CVU</a>) announced today that it shipped the first Low Rate Initial Production 3 (LRIP 3) pod structure to RTX Corporation as authorized under a previously announced contract award with a maximum value of $32.6 million. Pod structure deliveries on LRIP 3 are expected through mid-2025 after which CPI Aero anticipates transitioning to Lot 4 deliveries. In addition to the pod structures, CPI Aero produces air management system (AMS) components integral to the Next Generation Jammer Mid-Band (NGJ-MB) program.

CPI Aerostructures Delivers First Pod Structure Of Latest Production Contract For Next Generation Jammer Mid-Band Program To Raytheon, Under A Previously Announced Contract Award With A Maximum Value Of $32.6M

Company anticipates initial human trials to focus on AML upon IND clearance
SOUTH SAN FRANCISCO, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=y_dDazXZhDSmPgyiigFaCrTYCrWEF8S5uEHwoUPVBcKO2jm_s4t1EG8fsYd1wCGf_xHtdfLyht_Iv58thWuZIT0Mbssyyb20DadUDTFtBug=">CERo Therapeutics Holdings, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces presentation of a poster on its lead compound CER-1236 at the Global Cell &amp; Gene Therapy Summit 2024.&nbsp; The conference is being held July 8-10 in Boston.&nbsp; &nbsp;&nbsp;
The poster, titled, "Aberrant Expression of TIM-4-L is a Common Feature of AML and Potential Target for Engineered T Cell Therapy" presents data showing that TIM-4-L is prevalent on multiple acute myeloid leukemia (AML) subsets, but not present in healthy tissue.&nbsp; The study continues that CER-1236, CERo's lead compound, showed potent in vitro and in vivo cytotoxicity against TP53 mutant AML.&nbsp; Further, a full-scale toxicity study revealed that CER-1236 T cells engraft in lymphoid tissues, but do not cause any in-life observations, clinical pathology, or histopathological evaluations.&nbsp; This indicates that CER-1236 is not associated with any adverse toxicities against healthy tissue, even at high doses.&nbsp; The poster, which is being presented on July 8, 2024, can be accessed <a href="https://www.globenewswire.com/Tracker?data=WctxRYuKMcVz6dzaL4AhWmhkz7wzijYK_X5EeuOpxTum9Q46sWUtedqXI2LejbqQo-YP2n_7ES7LuI_JFdoYmY9-SjNhN5pf0i6hpSGSc3E=">here</a>.

CERO

CERo Therapeutics To Present CER-1236 Data Supporting Use In AML At Global Cell & Gene Therapy Summit 2024; Anticipates Initial Human Trials To Focus On AML Upon IND Clearance

Management

KORE

KORE Group Appoints Bruce Gordon As Executive Vice President And Chief Operating Officer, Effective July 2, 2024

Silicon Motion Technology Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) (&quot;Silicon Motion&quot; or the &quot;Company&quot;), a global leader in NAND flash controllers for solid state storage devices, announces that based on its preliminary&nbsp;second quarter&nbsp;financial results, sequential revenue growth is expected to be slightly above the high-end of its original&nbsp;guidance&nbsp;range of&nbsp;$199 million&nbsp;to&nbsp;$208 million, which the company issued on May 3, 2024. Gross margin (non-GAAP) is expected to be near the high-end of the company&#39;s original&nbsp;45.0%&nbsp;to&nbsp;46.0%&nbsp;guidance&nbsp;range.

SIMO

Silicon Motion Announces Preliminary Q2 2024 Revenue Above The High-end Of Its Original Guidance Range Of $199M-$208M Vs $203.88M Est

Although U.S. stocks closed higher on Friday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Noble</h3>
<ul>
<li>The Trade: Noble Corporation plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) 10% owner APMH Invest A/S <a href="https://www.benzinga.com/quote/NE/analyst-ratings">acquired a total of 300,000 shares</a> at an average price of $44.15. To acquire these shares, it cost around $13.2 million.</li>
<li>What's Happening: Last month, Noble announced an agreement to acquire Diamond Offshore Drilling, Inc. for $2.15 billion in a cash &amp; stock deal.</li>
<li>What Noble Does: Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units.</li>
</ul>
<h3 class="wp-block-heading">Friedman Industries</h3>
<ul>
<li>The Trade: Friedman Industries, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRD#NYSE">FRD</a>) Director, President / CEO Mike J Taylor acquired a total of 5,000 shares at an average price of $14.50. To acquire these shares, it cost around $72,500.</li>
<li>What's Happening: On June 26, Friedman Industries declared a cash dividend of 4 cents per share.</li>
<li>What Friedman Industries Does: Friedman Industries Inc is engaged in the manufacturing and processing of steel products.</li>
</ul>
Don&#8217;t forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<h3 class="wp-block-heading">Dave &amp; Buster&#8217;s Entertainment</h3>
<ul>
<li>The Trade: Dave &amp; Buster&#8217;s Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) CFO Darin Harper <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 13,578 shares</a> at an average price of $38.77. To acquire these shares, it cost around $526,420.</li>
<li>What's Happening: On June 12, Dave &amp; Buster&#8217;s reported worse-than-expected first-quarter financial results.</li>
<li>What Dave &amp; Buster&#8217;s Entertainment Does: Dave &amp; Buster&#8217;s Entertainment Inc owns and operates nearly a hundred entertainment and dining establishments in the United States where customers can eat, drink, play games, and watch televised sports.</li>
</ul>
<h3 class="wp-block-heading">First National</h3>
<ul>
<li>The Trade: First National Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FXNC#NASDAQ">FXNC</a>) Director Kirtesh Patel <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 7,500 shares</a> at an average price of $15.56. The insider spent around $116,700 to buy those shares. </li>
<li>What's Happening: On April 30, First National Corporation reported unaudited consolidated net income of $3.2 million for the three months ended March 31, 2024.</li>
<li>What First National Does: First National Corp is a bank holding company of First Bank, which is a commercial bank.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39646161/top-3-financial-stocks-youll-regret-missing-in-q3">Top 3 Financial Stocks You&#8217;ll Regret Missing In Q3</a>

Long Ideas

Insider Trades

Pre-Market Outlook

Trading Ideas

FXNC

PLAY

Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying

Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indication
Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aavantgarde.com%2F&amp;esheet=54090622&amp;newsitemid=20240708617840&amp;lan=en-US&amp;anchor=AAVantgarde&amp;index=1&amp;md5=b572b08a09dcb17591599e229a56e259">AAVantgarde</a> today announced a contract development and manufacturing organization (CDMO) agreement to produce Good Manufacturing Practice- (GMP) plasmid DNA. AAVantgarde, a clinical-stage biotechnology company with two proprietary adeno-associated viral (AAV) vector platforms for large gene delivery and developing products to treat inherited retinal diseases, will leverage Charles River's expertise in manufacturing GMP plasmid DNA.
AAVantgarde has two proprietary AAV-based large gene delivery platforms, both of which aim to enable efficient delivery of large genes to tissue and cells in vivo. Within this collaboration, Charles River will develop the plasmid DNA for AAVantgarde's Stargardt's disease program (AAVB-039), using their AAV-intein platform, which has demonstrated a very efficient recombination to deliver therapeutically meaningful protein levels.
 &nbsp;